/CBUS
CBUS Stock - Cibus, Inc.
Healthcare|BiotechnologyNASDAQ
$1.71+11.04%
+$0.17 (+11.04%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.66
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.55
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+562.6%upside
Target: $11.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CBUS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.69 – $1.73
TARGET (TP)$11.33
STOP LOSS$1.57
RISK/REWARD1:68.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.63
52W High$3.40
52W Low$1.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.26M | $1.82M | $157,000 | $25.99M | $23.85M |
| Gross Profit | $4.26M | $1.42M | $-1,377,000 | $-2,570,000 | $-11,276,000 |
| Gross Margin | 100.0% | 78.3% | -877.1% | -9.9% | -47.3% |
| Operating Income | $-258,396,000 | $-318,883,000 | $-22,370,000 | $-29,332,000 | $-43,832,000 |
| Net Income | $-251,388,000 | $-267,627,000 | $-16,891,000 | $-29,199,000 | $-44,836,000 |
| Net Margin | -5898.4% | -14729.1% | -10758.6% | -112.4% | -188.0% |
| EPS | $-10.83 | $-25.95 | $-0.03 | $-0.05 | $-66.16 |
Company Overview
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$26
Average Target
↑ 1391.2% Upside
Now
$22
Low
$26
Average
$30
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 29th 2024 | Alliance Global Partners | Initiation | Buy | $25 |
| July 19th 2024 | Canaccord Genuity | Resumed | Buy | $22 |
| October 9th 2023 | H.C. Wainwright | Initiation | Buy | $25 |
| July 19th 2023 | Canaccord Genuity | Resumed | Buy | $30 |
Earnings History & Surprises
CBUSBeat Rate
43%
Last 14 quarters
Avg Surprise
-40.5%
EPS vs Estimate
Beats / Misses
6/8
Last 12 quarters
Latest EPS
$-0.44
Q4 2025
EPS Surprise History
Q1 24
-3.6%
$-1.16vs$-1.12
Q2 24
-10.9%
$-1.12vs$-1.01
Q3 24
-40.7%
$-1.14vs$-0.81
Q4 24
+106.7%
$0.06vs$-0.90
Q1 25
-27.9%
$-0.87vs$-0.68
Q2 25
-5.7%
$-0.74vs$-0.70
Q3 25
+11.6%
$-0.61vs$-0.69
Q4 25
-7.3%
$-0.44vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.43 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.41 | $-0.44 | -7.3% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.69 | $-0.61 | +11.6% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.70 | $-0.74 | -5.7% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.68 | $-0.87 | -27.9% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.90 | $0.06 | +106.7% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.81 | $-1.14 | -40.7% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-1.01 | $-1.12 | -10.9% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-1.12 | $-1.16 | -3.6% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-1.18 | $-1.59 | -34.7% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.30 | $-3.05 | -916.7% | ✗ MISS |
Q2 2023 | May 1, 2023 | $-3.00 | $-1.09 | +63.7% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-5.50 | $-0.06 | +98.9% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | $-7.00 | $-0.01 | +99.9% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 31, 2022 | $-6.83 | $-0.01 | +99.9% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.01 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Latest News
Cibus Welcomes EU Agreement On New Genomic Techniques Framework Following Call For Action From Agri‑Food Organizations
📈 PositiveBenzinga•Dec 11, 2025, 12:10 PM
Cibus shares are trading lower after the company reported worse-than-expected Q3 sales results.
📉 NegativeBenzinga•Nov 13, 2025, 09:17 PM
Cibus Q3 EPS $(0.44) Beats $(0.52) Estimate, Sales $615.000K Miss $1.391M Estimate
➖ NeutralBenzinga•Nov 13, 2025, 09:07 PM
Cibus Agrees With AgVayā To Develop Strategies And Solutions For Indian Agriculture Market
📈 PositiveBenzinga•Oct 16, 2025, 11:57 AM
Cibus Completes Field Testing For Second-Generation Herbicide Tolerance Edited Canola With Positive Results
📈 PositiveBenzinga•Oct 2, 2025, 11:08 AM
Cibus Appoints Cornelis Broos As CFO
➖ NeutralBenzinga•Sep 23, 2025, 08:26 PM
Cibus Partners With CIAT to Bring Herbicide-Tolerant Rice Hybrids to Farmers in Latin America
📈 PositiveBenzinga•Aug 28, 2025, 11:21 AM
Frequently Asked Questions about CBUS
What is CBUS's current stock price?
Cibus, Inc. (CBUS) is currently trading at $1.71 per share. The stock has moved +11.04% today.
What is the analyst price target for CBUS?
The average analyst price target for CBUS is $11.33, based on 1 analyst.
What sector is Cibus, Inc. in?
Cibus, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CBUS's market cap?
Cibus, Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does CBUS pay dividends?
No, Cibus, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
CAMP
CAMP4 Therapeutics Corporation
$6.38
Mkt Cap: $0.1B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
MNOV
MediciNova, Inc.
$1.43
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
UNCY
Unicycive Therapeutics, Inc.
$5.56
Mkt Cap: $0.1B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
Explore stocks similar to CBUS for comparison